Opinion|Videos|December 29, 2023
Clinical Data on the Approved JAK Inhibitors for Treatment of Myelofibrosis
Author(s)Christine Cooper, RN, BSN, Aaron Gerds, MD, MS
An expert discusses the four FDA-approved JAK inhibitors for myelofibrosis - ruxolitinib, fedratinib, pacritinib, and momelotinib.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on CURE
1
An Oncology Physical Therapist Explains Why Movement Matters Most During Cancer Treatment
2
Top 5 Takeaways From EHA 2026 That Patients Should Know
3
Of Course I Worry: Living With Uncertainty Six Years After Remission
4
Every Holiday, A Milestone: My Sister's 11-Year Cancer Journey
5